Biointron Weekly Reports
News???
Introducing our High-throughput Fully Humanized Antibody Discovery Platform with Biointron AbDrop? & Cyagen HUGO-Ab?! ?? ?
?? Register for our next webinar: “Accelerating Antibody Drug Discovery with Fully Human Antibody Mouse HUGO-Ab and High-Throughput Single B Cell Screening”, on December 9, 9PM EST // December 10, 9AM Beijing Time.
Biointron has achieved a high certification in a recent third-party risk assessment conducted by CyberVadis! ?? This comprehensive assessment, which evaluated our entire organization and all functions, underscores our commitment to excellence in cybersecurity and risk management. CyberVadis is a leading global provider of independent cybersecurity assessment services, and their rigorous evaluation process includes international standards such as ISO 2700x, NIST Cybersecurity Framework, ICS Cybersecurity, and GDPR.?
In our latest episode of the Antibody Basics video series (Part 13), we cover?immune checkpoint inhibitors (ICIs) as therapeutic targets for antibody drugs. Watch it now.
?
This Week’s News?
Trends – Hepatitis B Virus (HBV)
Hepatitis B virus (HBV) infection is a major global health issue, driven by high levels of immunosuppressive viral antigens, the host immune system's failure to effectively control the virus, and the immunosuppressive environment of the liver. Existing therapies have?limited effectiveness in eliminating the hepatitis B surface antigen (HBsAg). Antibody-based treatments have shown promise in neutralizing the virus and clearing HBsAg, but achieving effective virologic control often requires high doses or frequent administration.
Currently, several different antibody drug types are being developed. This week, the HBV antibody GIGA-2339 was cleared for phase I clinical trials, following a recent FDA approval of the GigaGen Inc ’s investigational new drug (IND) application. GIGA-2339 is the first recombinant human polyclonal antibody treatment for HBV. The drug consists of?over?1,000 anti-HBV antibodies developed in the laboratory by capturing and then reproducing the natural antibody response from donors who have been vaccinated against HBV.?It?is more than 2,000 times more potent than plasma-derived HBV drugs and covers the large diversity of circulating HBV variants.?
Meanwhile in the research space,?a?team at 厦门大学 have introduced an immune-stimulating?ADC?made up of a?TLR7/8 agonist small molecule compound IMDQ?linked to an anti-HBsAg antibody 129G1. Preliminary?results of this dual-targeting antibody-drug conjugate (ADC) demonstrated?robust and sustained anti-HBsAg specific reactions with short-term administration, and a strong and lasting anti-HBsAg immune response after short-term treatment in AAV/HBV mice. ?
Furthermore, researchers from Ospedale San Raffaele found that CD8-IL2 treatment exhibited antiviral activity in a preclinical model of chronic HBV, reducing viremia; further data in human cells and cynomolgus monkeys supported the specificity and safety of this molecule. The team developed and tested a CD8 cis-targeted IL-2 (CD8-IL2) that selectively activates CD8+ T cells without affecting regulatory T cells or natural killer cells, since traditional IL-2–based therapies are plagued by toxicities and unintended activation of other immune cell populations. Their results support further development of CD8-IL2 for chronic HBV.
However, a mini-review discusses how HBV reactivation poses a significant clinical challenge, especially in patients undergoing immunosuppressive therapies, including monoclonal antibodies. HBV reactivation is a potentially fatal complication after immunosuppressive biological or targeted therapy. Reports from the literature demonstrate that this is more frequent in patients treated with anti-CD20 or anti-TNF. However, there are some case reports of other mAbs causing this adverse event. Many unanswered questions remain about the risk of HBV reactivation associated with recently introduced mAbs. These questions provide an opportunity for monitoring and research.
领英推荐
Upcoming Events
Next month we will also be exhibiting at the 15th World Bispecific Summit on September 3-5 in Boston, MA. The summit is the industry’s one-stop-shop for all your strategic needs within bi, tri or multi-specifics or even bispecific ADCs or BiTEs. Hosted by Hanson Wade Group and held at the Royal Sonesta Boston, we look forward to meeting you!
Promotions – 40% OFF Abinvivo Products! ??
Save on Your Next Project with Abinvivo Reagents! Biointron is excited to announce a ????% ????????-???????? ???????????????? on our top-quality in vivo reagent products at the Biointron sub-brand, Abinvivo! Now with online check-out and 1 week delivery!
????????'?? ????????????????:?
?????????????????? ???????????????? ?????????????????
?????????????? ???????????????? ?????????????????
????????-?????????? ?????????????????
???????????????????? ?????????????????????
...?????? ????????!?
?? ?????? ???????????? ?????? ?????????????? ??????????????????
Don't miss out on this fantastic opportunity to enhance your research with top-tier reagents at unbeatable prices: https://www.abinvivo.com/abinvivo/Home?
RushMab? - Gene is your go-to solution for quick plasmid production, designed specifically for antibody-related research. We offer a 4-day turnaround, delivering high-quality, transfection-grade expression plasmids for IgG, Fab, VHH, and ScFv sequences. We provide quantities of 100 μg (sufficient for 100 ml culture) with scalability up to grams. Using the reliable pcDNA3.4 backbone, we also accommodate custom vectors. Each plasmid undergoes Sanger sequencing verification and endotoxin control, ensuring precision and safety.
?
New Products & Reports?
Learn more about Biointron at www.biointron.com, or contact us at [email protected] and +1 (732) 790-8340.?